Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer. […]
ABIRATERONE EXPANDED ACCESS Trial Site Contact Info – 3/25/11 for men with advanced prostate cancer (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic prostate cancer 3. no brain metastasis 4. failed chemo 5. no more than 2 different types of previous chemo […]
Bristol-Myers Squibb Co. announced today (March 25) that it has received FDA approval for ipilimumab, the first drug in a new family of medicines to treat advanced melanoma, the most deadly form of skin cancer. This is potentially good news for those of us who are fighting advanced prostate cancer as there is currently an [...]
Increasingly it has become obvious to me and to many other individuals that our current drug approval and development process has a basic flaw. If you go to research conferences you quickly learn that there is probably no magic bullet to stop any type of cancer, including advanced prostate cancer. Current drug development focuses on [...]
Firmagon, the newly FDA approved gonadotropin-releasing hormone (GnRH) receptor blocker should perhaps be considered as a better alternative to the traditionally used ADT drugs like lupron and zoladex (GnRH agonists) which are the current standard of care. Recent data released from the ongoing five-year Firmagon (degarelix) extension study (CS21a) has demonstrated the long term efficacy [...]